Exalenz Bioscience (Israel) Management Performance Evaluation

EXEN -- Israel Stock  

ILS 1,026  18.00  1.72%

Analysis of Exalenz Bioscience manpower and management performance can provide insight into Exalenz Bioscience stock performance. Also an employee sentiment is becoming a valuable factor that investors can use to determine the amount of risk that may be associated with Exalenz Bioscience future performance. Additionally see Investing Opportunities.

Exalenz Bioscience Management Effectiveness

The company has return on total asset (ROA) of (29.93) % which means that it has lost $29.93 on every $100 spent on asset. This is way below average.

Exalenz Bioscience Profit Margins

The company has Profit Margin (PM) of (40.19) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (39.94) % which suggests for every $100 dollars of sales it generated a net operating loss of -0.4.

Exalenz Bioscience Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of seventeen. Exalenz Bioscience Price Series Summation is a cross summation of Exalenz Bioscience price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

Exalenz Bioscience Stakeholders

Uri Geiger Chairman of the Board
Susan Alpert Vice President of Regulation
Ari Soae Vice President-Supply Chain
Eitan Blank Vice President - Operations
Nisim Bilman Vice President - Research & Development
Michal Hershkovitz Vice President-Regulation & Quality Assurance
Ofer Schlesinger Vice President - Research & Development
Mark Hod Vice President of Sales, North America
Roy Golan President Vice President - Finance
David Stolick CFO
Raphael Werner COO
Ilan Oren CTO
Nachum Shamir Director
Shmuel Rubinstein Director
Saul Yemal External Director
Avi Zigelman External Director
Itai Arkin Director
Sharon Kochan External Director
Gad Keren External Director
Menachem Inbar Director
Einat Zisman Director
Niza Lipshitz External Director

Exalenz Bioscience Leadership

Exalenz Bioscience Top Executives

  Uri Geiger  Chairman
Chairman of the Board
  Susan Alpert  President
Vice President of Regulation

Exalenz Bioscience Tenure Analysis

Exalenz Bioscience Employment Tenure

Exalenz Bioscience employes about 17 people. The company is managed by 22 executives with total tenure of roughly 110 years, averanging almost 5.0 years of service per executive having 0.0 employee per reported executive.

Exalenz BioscienceManpower Efficiency

Return on Exalenz Bioscience Manpower

Revenue Per Employee648.8 K
Revenue Per Executive501.4 K
Net Loss Per Employee260.6 K
Net Loss Per Executive201.4 K
Working Capital Per Employee1.5 M
Working Capital Per Executive1.2 M
Additionally see Investing Opportunities. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Search macroaxis.com